Kairos Pharma unveils new investor presentation

Q: What did Kairos Pharma (KAPA) announce in this Form 8-K?

Kairos Pharma announced that it issued a new investor presentation, which will be posted on its website and presented at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY from September 14–16, 2026.

Q: Who will present Kairos Pharma’s new investor presentation and what will it cover?

Chief Executive Officer John Yu will present the new investor presentation at the conference. The presentation is intended to provide an update on Kairos Pharma’s clinical program and activities.

Q: Where can investors access Kairos Pharma’s new investor presentation?

The new investor presentation will be published on Kairos Pharma’s website, www.kairospharma.com, and a copy is furnished as Exhibit 99.1 to the Form 8-K.

Q: Is Kairos Pharma’s investor presentation considered filed for Exchange Act purposes?

No. The information in Item 7.01, including Exhibit 99.1, is being furnished and is explicitly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into Securities Act or Exchange Act filings.

Q: What exhibits did Kairos Pharma include with this 8-K for KAPA?

Kairos Pharma included two exhibits: Exhibit 99.1, which is the Investor Presentation, and Exhibit 104, the Cover Page Interactive Data File with XBRL tags embedded within the Inline XBRL document.

Kairos Pharma, Ltd. (KAPA) announced that on September 14, 2026 it issued a new investor presentation that will be posted on its website and presented at the H.C.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Kairos Pharma, Ltd. (KAPA) announced that on September 14, 2026 it issued a new investor presentation that will be posted on its website and presented at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY from September 14–16, 2026. Chief Executive Officer John Yu will use this presentation to provide an update on the company’s clinical program and activities. The investor presentation is furnished as Exhibit 99.1 and is not deemed filed or incorporated by reference for Securities Act or Exchange Act purposes.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Regulation FD, Emerging growth company, Inline XBRL, investor presentation

4 terms

Regulation FD regulatory

"Item 7.01. Regulation FD Disclosure."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"XBRL tags are embedded within the Inline XBRL Document"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

investor presentation financial

"issued a new investor presentation, which will be published"

An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kairos Pharma (KAPA) announce in this Form 8-K?

Kairos Pharma announced that it issued a new investor presentation, which will be posted on its website and presented at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY from September 14–16, 2026.

Who will present Kairos Pharma’s new investor presentation and what will it cover?

Chief Executive Officer John Yu will present the new investor presentation at the conference. The presentation is intended to provide an update on Kairos Pharma’s clinical program and activities.

Where can investors access Kairos Pharma’s new investor presentation?

The new investor presentation will be published on Kairos Pharma’s website, www.kairospharma.com, and a copy is furnished as Exhibit 99.1 to the Form 8-K.

Is Kairos Pharma’s investor presentation considered filed for Exchange Act purposes?

No. The information in Item 7.01, including Exhibit 99.1, is being furnished and is explicitly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into Securities Act or Exchange Act filings.

What exhibits did Kairos Pharma include with this 8-K for KAPA?

Kairos Pharma included two exhibits: Exhibit 99.1, which is the Investor Presentation, and Exhibit 104, the Cover Page Interactive Data File with XBRL tags embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/14/2026 - 04:01 PM Accepted by SEC EDGAR 09/14/2026 - 04:00 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 14, 2026

Kairos Pharma, Ltd.

(Exact name of registrant as specified in its charter)

Delaware

001-42275

46-2993314

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2355 Westwood Blvd., #139

Los Angeles CA 90064

(Address of principal executive offices) (Zip Code)

(310) 948-2356

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol (s)		Name of each exchange on which registered
Common Stock, par value $0.001, per share		KAPA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 14, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”), issued a new investor presentation, which will be published on the Company’s website, www.kairospharma.com, and presented at the H.C. Wainwright 28^th Annual Global Investment Conference (the “Conference”), set to take place in New York, NY from September 14-16, 2026. As part of its participation in the Conference, the Company’s Chief Executive Officer, John Yu, will present the investor presentation to provide an update on the Company’s clinical program and activities.

A copy of the investor presentation is being furnished as Exhibit 99.1 to this Form 8-K. The information included in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Document
99.1		Investor Presentation
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.